Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

JP Morgan Stock Is Hurtling Toward a Reality Check in Q3

By Josh Enomoto, InvestorPlace Contributor

JP Morgan has produced some strong earnings results in the past. However, the upcoming Q3 report promises to be a far different test as this is the quarter that saw the introduction of reduced borrowing costs from the Fed.

It’s Time to Go Storm-Watching With Apple Stock

By Josh Enomoto, InvestorPlace Contributor

Typically, a strong product and services portfolio should bolster Apple stock, and that’s exactly what’s happening now. However, with so many headwinds bearing down on the consumer tech giant, it’s best to avoid this name.

5 Semiconductor Stocks Worth Your Time

By Josh Enomoto, InvestorPlace Contributor

The extremely challenging U.S.-China relations poses a nearer-term threat to semiconductor stocks. However, investors should consider that the semis represent technological progress and progress is always about moving forward.

Alibaba Stock May Be Stuck in a Political Bear Trap Longer Than We Think

By Josh Enomoto, InvestorPlace Contributor

There’s no point in fighting the tape: if the U.S. and China cannot secure a trade negotiation, Alibaba stock is more likely to sink first before moving higher.

Here’s How the Mandela Effect Has Hurt Cronos Group Stock

By Josh Enomoto, InvestorPlace Contributor

Hysteria over the vaping crisis has hurt CRON stock. But investors should have patience until all the facts are straightened out.

Load More